Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido

Journal of Clinical Endocrinology and Metabolism

Volumn 73, Issue 6, 1991, Pages 1360-1369

  Pavlou, Spyros N ^a   Brewer, Kim ^a   Farley, M Ginnie ^a   Lindner, Jill ^a   Bastias, Maria Cristina ^a   Rogers, B Jane ^a   Swift, Larry L ^a   Rivier, Jean E ^c   Valef, Wylie W ^c   Conn, P Michael ^b   Herbert, Carl M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; GONADORELIN; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; LUTEINIZING HORMONE; TESTOSTERONE ENANTATE;

ADULT; ARTICLE; AZOOSPERMIA; CLINICAL ARTICLE; CONTRACEPTION; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEMEN ANALYSIS; SPERMATOZOON MOTILITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANDROGENS; BIOLOGY; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVE AGENTS, MALE; ENDOCRINE SYSTEM; EXAMINATIONS AND DIAGNOSES; FAMILY PLANNING; FOLLICLE STIMULATING HORMONE--ANALYSIS; GENITALIA; GENITALIA, MALE; GONADOTROPINS; GONADOTROPINS, PITUITARY; HORMONE ANTAGONISTS--ADMINISTRACTION AND DOSAGE; HORMONES; LABORATORY EXAMINATIONS AND DIAGNOSES; LABORATORY PROCEDURES; LUTEINIZING HORMONE--ANALYSIS; PHYSIOLOGY; SEMEN--ANALYSIS; SEMINAL VESICLES; SPERM COUNT; TESTOSTERONE--ADMINISTRACTION AND DOSAGE; TESTOSTERONE--ANALYSIS; UROGENITAL SYSTEM;

ADULT; CELL SURVIVAL; CONTRACEPTIVE AGENTS, MALE; DRUG COMBINATIONS; GONADORELIN; HUMAN; LIBIDO; LIPIDS; MALE; MIDDLE AGE; OLIGOSPERMIA; SEX HORMONES; SPERM COUNT; SPERM MOTILITY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TESTOSTERONE;

EID: 0025751705     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem-73-6-1360     Document Type: Article

References (50)

1. Mishell Jr DR. Contraception. N Engl J Med. 1989;320:777-87.
2. Bremner WJ, Matsumoto AM, Paulsen CA. Gonadotropin control of spermatogenesis in man: studies of gonadotropin administration in spontaneous and experimentally induced hypogonadotropic states. Ann NY Acad Sci. 1984;438:465-71.
3. Petitti DB. Epidemiologic studies of vasectomy. In: Zatuchni GI, Goldsmith A, Spieler JM, Sciarra JJ, eds. Male contraception. Philadelphia: Harper and Row; 1986;24-33.
4. Paulsen CA, Bremner WJ, Leonard JM. Male contraception: clinical trials. In: Mishell DR, ed. Advances in fertility research. New York: Raven Press; 1982;157-70.
5. Wu FC. Male contraception: current status and future prospects. Clin Endocrinol (Oxf). 1988;29:443-65.
6. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990;336:955-9.
7. Wu D. An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs. 1989;38:333-41.
8. Conn PM, Huckle WR, Andrews WV, McArdle CA. The molecular mechanism of action of gonadotropin releasing hormone (GnRH) in the pituitary. Recent Prog Horm Res. 1987;43:29-68.
9. Negro Vilar A, Valenca MM, Culler MD. Transmembrane signals and intracellular messengers mediating LHRH and LH secretion. Adv Exp Med Biol. 1987;219:85-108.
10. Santen RJ, Bourguignon JP. Gonadotropin-releasing hormone: physiological and therapeutic aspects, agonists and antagonists. Horm Res. 1987;28:88-103.
11. Rabin D, McNeil LW. Pituitary and gonadal desensitization after continuous luteinizing hormone-releasing hormone infusion in normal females. J Clin Endocrinol Metab. 1980;51:873-6.
12. Monroe SE, Blumenfeld Z, Andreyko JL, Schriock E, Henzl MR, Jaffe RB. Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin). J Clin Endocrinol Metab. 1986;63:1334- 41.
13. Boepple PA, Mansfield MJ, Wierman ME, et al. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev. 1986;7:24-33.
14. Linde R, Doelle GC, Alexander N, et al. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med. 1981;305:663-7.
15. Swerdloff RS, Handelsman DJ, Bhasin S. Hormonal effects of GnRH agonist in the human male: an approach to male contraception using combined androgen and GnRH agonist treatment. J Steroid Biochem. 1985;23:855-61.
16. Schurmeyer T, Knuth UA, Freischem CW, Sandow J, Akhtar FB, Nieschlag E. Suppression of pituitary and testicular function in normal men by constant gonadotropin-releasing hormone agonist infusion. J Clin Endocrinol Metab. 1984;59:19-24.
17. Pavlou SN, Interlandi JW, Wakefield G, Rivier J, Vale W, Rabin D. Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone. J Androl. 1986;7:228-33.
18. Bhasin S, Yuan QX, Steiner BS, Swerdloff RS. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in men: effects of long term treatment with GnRH agonist infusion and androgen. J Clin Endocrinol Metab. 1987;65:568-74.
19. Pavlou SN, Dahl KD, Wakefield G, et al. Maintenance of the ratio of bioactive to immunoreactive follicle-stimulating hormone in normal men during chronic luteinizing hormone-releasing hormone agonist administration. J Clin Endocrinol Metab. 1988;66:1005-9.
20. Santen RJ, Demers LM, Max DT, Smith J, Stein BS, Glode LM. Long term effects of administration of a gonadotropin-releasing hormone superagonist in men with prostatic carcinoma. J Clin Endocrinol Metab. 1984;58:397-400.
21. Perrin MH, Haas Y, Rivier JE, Vale WW. Gonadotropin-releasing hormone binding to rat anterior pituitary membrane homogenates. Comparison of antagonists and agonists using radiolabeled antagonist and agonist. Mol Pharmacol. 1983;23:44-51.
22. Wierman ME, Rivier JE, Wang C. Gonadotropin-releasing hormone-dependent regulation of gonadotropin subunit messenger ribonucleic acid levels in the rat. Endocrinology. 1989;124:272-8.
23. Dahl KD, Pavlou SN, Kovacs WJ, Hsueh AJ. The changing ratio of serum bioactive to immunoreactive follicle-stimulating hormone in normal men following treatment with a potent gonadotropin releasing hormone antagonist. J Clin Endocrinol Metab. 1986;63:792-4.
24. Pavlou SN, Veldhuis JD, Lindner J, et al. Persistence of concordant luteinizing hormone (LH), testosterone, and alpha-subunit pulses after LH-releasing hormone antagonist administration in normal men. J Clin Endocrinol Metab. 1990;70:1472-8.
25. Pavlou SN, Wakefield G, Schlechter NL, et al. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men. J Clin Endocrinol Metab. 1989;68:446-54.
26. Jockenhovel F, Bhasin S, Steiner BS, Rivier JE, Vale WW, Swerdloff RS. Hormonal effects of single gonadotropin-releasing hormone antagonist doses in men. J Clin Endocrinol Metab. 1988;66:1065-70.
27. Bagatell CJ, McLachlan RI, de Kretser DM, et al. A comparison of the suppressive effects of testosterone and a potent new gonadotropin-releasing hormone antagonist on gonadotropin and inhibin levels in normal men. J Clin Endocrinol Metab. 1989;69:43-8.
28. Hall JE, Brodie TD, Badger TM, et al. Evidence of differential control of FSH and LH secretion by gonadotropin-releasing hormone (GnRH) from the use of a GnRH antagonist. J Clin Endocrinol Metab. 1988;67:524-31.
29. Pavlou SN, Interlandi JW, Wakefield G, et al. Gonadotropins and testosterone escape from suppression during prolonged luteinizing hormone-releasing hormone antagonist administration in normal men. J Clin Endocrinol Metab. 1987;64:1070-4.
30. Schmidt F, Sundaram K, Thau RB, Bardin CW. [Ac-d-NAL(2)l, 4FD-Phe2, D-Trp3, DArg6]-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats. Contraception. 1984;29:283-9.
31. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499
32. Robertson WH. An illustrated history of contraception. Park Ridge: Parthenon Group; 1990.
33. Cooper JF. Technique of contraception. New York: Day-Nichols; 1928.
34. Himes NE. Medical history of contraception. New York: Gamut Press; 1963.
35. Awoniyi CA, Sprando RL, Santulli R, Chandrashekar V, Ewing LL, Zirkin BR. Restoration of spermatogenesis by exogenously administered testosterone in rats made azoospermic by hypophy-sectomy or withdrawal of luteinizing hormone alone. Endocrinology. 1990;127:177-84.
36. Akhtar FB, Marshall GR, Nieschlag E. Testosterone supplementation attenuates the antifertility effects of an LHRH agonist in male rhesus monkeys. Int J Androl. 1983;6:461-8.
37. Bouchard P, Garcia E. Influence of testosterone substitution on sperm suppression by LHRH agonists. Horm Res. 1987;28:175-80.
38. Steinberger E. Hormonal control of mammalian spermatogenesis. Physiol Rev. 1971;51:1-22.
39. Dahl KD, Bicsak TA, Hsueh AJ. Naturally occurring antihormones: secretion of FSH antagonists by women treated with a GnRH analog. Science. 1988;239:72-4.
40. Daneshdoost L, Pavlou SN, Molitch ME, et al. Inhibition of follicle-stimulating hormone secretion from gonadotroph adenomas by repetitive administration of a gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab. 1990;7:92-7.
41. Spratt DI, Finkelstein JS, Badger TM, Butler JP, Crowley Jr WF. Bio- and immunoactive luteinizing hormone responses to low doses of gonadotropin-releasing hormone (GnRH): dose-response curves in GnRH-deficient men. J Clin Endocrinol Metab. 1986;63:143-50.
42. Danforth DR, Gordon K, Leal JA, Williams RF, Hodgen GD. Extended presence of antide (Nal-Lys GnRH antagonist) in circulation: prolonged duration of gonadotropin inhibition may derive from antide binding to serum proteins. J Clin Endocrinol Metab. 1990;70:554-6.
43. Heller CG, Clermont Y. Spermatogenesis in man: an estimate of its duration. Science. 1963;140:184-6.
44. Rowley MJ, Teshima F, Heller CG. Duration of transit of spermatozoa through the human male ductular system. Fertil Steril. 1970;21:390-6.
45. Sorva R, Kuusi T, Dunkel L, Taskinen MR. Effects of endogenous sex steroids on serum lipoproteins and postheparin plasma lipolytic enzymes. J Clin Endocrinol Metab. 1988;66:408-13.
46. Friedl KE, Plymate SR, Paulsen CA. Transient reduction in serum HDL-cholesterol following medroxyprogesterone acetate and testosterone cypionate administration to healthy men. Contraception. 1985;31:409-20.
47. Wallace EM, Wu FC. Effect of depot medroxyprogesterone acetate and testosterone oenanthate on serum lipoproteins in man. Contraception. 1990;41:63-71.
48. Goldberg RB, Rabin D, Alexander AN, Doelle GC, Getz GS. Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-1 and B. J Clin Endocrinol. Metab. 1985;60:203-7.
49. Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J Clin Endocrinol Metab. 1988;66:314-22.
50. Nestor Jr JJ, Tahilramani R, Ho TL, McRae GI, Vickery BH. Potent, long-acting luteinizing hormone-releasing hormone antagonists containing new synthetic amino acids: N, N'-dialkyl-D-hom-oarginines. J Med Chem. 1988;31:65-72.